Excipient: Super Refined™ DEGEE

Super Refined CCMG 400 is a multi-compendial, high purity mixture of caprylocaproyl polyoxylglycerides. This product has undergone intense purification, by which impurities and other reactive species that could negatively impact API and formulation stability have been removed.

Pharmacopoeia ...

• Quillaja saponaria Molina is a South American tree native to Chile whose bark is rich in a complex mixture of triterpenic saponins • Quillaja-derived saponins such as Quil-A® are currently used as veterinary vaccine adjuvants • One specific fraction of the Quil-A saponin mixture, QS-21, is an extreme...

The formulation of active pharmaceutical ingredients (APIs) for parenteral applications demands the highest quality standards and attention to detail. Excipient selection is critical to drug stability, formulation integrity and patient safety.
Croda’s Super Refined™ excipients offer multiple benefit...

Super Refined Polysorbates solubilise and stabilise the most sensitive active ingredients across dosage forms including injectable and oral. Super Refining removes impurities (including primary and secondary oxidation products) from an excipient without altering its chemical composition, helping to reduce...

• Alhydrogel is a range of aluminium hydroxide gel products which have been specifically developed for use as an adjuvant in human and veterinary vaccines • The gel is a suspension of boehmite-like (aluminium oxyhydroxide) hydrated nano/micron size crystals in loose aggregates • The products have very...

There is a growing need to address the challenges that can affect topical drug delivery, such as: API instability, poor API solubilisation and skin irritation that reduces patient compliance. Croda’s Super Refined™ excipients can maximise the value of topical drug products and address formu...

Super Refined P35 Castor Oil is a castor oil derivative, resulting from the reaction of glycerol ricinoleate and 35 mols of ethylene oxide. This product is a liquid nonionic solubiliser and emulsifier, characteristic of a slightly yellow hue, and is intended for use in parenteral, ophthalmic, oral, and to...

Oral drug development often faces numerous challenges including: poor solubility, formulation instability and ineffective drug delivery. The selection of the right oral excipient during early phase development is critical to creating a successful oral drug product.
Croda’s Super Refined™ e...

• Quil-A is a highly purified and concentrated saponin adjuvant purified from bark extract of the Quillaja saponaria Molina tree which has been specifically developed for use as an adjuvant in vaccines • Quil-A saponin was originally purified and characterised by Dr. Pharm • Kristian Dalsgaard in 1974...

Super Refined PEGs are solvents for use with the most sensitive active ingredients across dosage forms including injectable and oral. Super Refining removes polar impurities (including primary and secondary oxidation products) from an excipient without altering its chemical composition, reducing excipient...

• Adju-Phos® is a range of aluminium phosphate gel products which have been specifically developed for use as an adjuvant in vaccines • The gel is a suspension of hydrated amorphous aluminium hydroxyphosphate nano/micron size crystal in loose aggregates. Adju-Phos products have a net negative charg...

Super Refined Polysorbates solubilise and stabilise the most sensitive active ingredients across dosage forms including injectable and oral. Super Refining removes impurities (including primary and secondary oxidation products) from an excipient without altering its chemical composition, helping to reduce...

Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.

More then lipids. Solutions for the entire product cycle: research to commercialisation. Immunotherapy and vaccine development. The recent Avanti acquisition by Croda Health Care grows the expertise and resource available to our customers. Croda Health Care is growing.

Adjuvants. You’ve seen them on our website. You’ve seen them featured in our blog articles. Now we want to show you how Avanti’ & Croda-Denmark can enhance your vaccine adjuvant research!

Keep reading to learn more!

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

The facility will support the company'a goal of being climate, land and people positive by 2030.

Looking to enhance the bioavailability, delivery and efficacy of your dosage form? With Croda's high purity excipients and delivery aids you can optimise the stability of your API and the overall performance of your pharmaceutical formulations. These excipients are ideal for multiple dosage forms including topical, parenteral, oral and ophthalmic formulations as well as advanced delivery systems.

The transaction will more than double Croda’s R&D capability in drug delivery.

A presentation about Croda Health Care's vision for our Consumer Health market

Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.

FDAII Nasal and Auricular

Croda has strengthened its pharmaceutical offering by acquiring Brenntag Biosector (Biosector), for a total consideration of €72 million in cash.

FDAII Ophthalmic

FDAII Oral

FDAII Topical

FDAII Transdermal

FDAII Vaginal / Rectal

Super Refined Benzyl Alcohol is a multi-compendial, high purity aromatic alcohol intended for parenteral dosage forms. This clear, colourless liquid can be used as a preservative, solvent, viscosity reducing agent, or local anesthetic in pharmaceutical applications.1 Unlike some standard grades of benzyl alcohol, Super Refined Benzyl Alcohol is compliant to multiple parenteral monographs and can therefore be used in injectable and other parenteral dosage forms, where excipient purity is crucial. This allows for comprehensive usage of only one product, reducing the need to find a second source for more restrictive applications.

To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.

For over 40 years Avanti has provided API (Active Pharmaceutical Ingredient) Technology Development for Pharmaceutical and Biotechnology companies. Our unique reputation for quality in the development of pre-clinical and clinical candidates is well established. Our full range of services include process chemistry, scale-up manufacturing, supply chain management with analytical and regulatory requirements. Avanti’s experienced staff of chemists and lipid analysts are ready to meet your development needs with pre-clinical through phase III and commercial launch.

The Avanti Formulations Team can help develop a suitable formulation for your lipid-based formulation.With the vast library of Avanti lipids and state-of-the-art equipment at our disposal, this experienced team can produce surface-labeled, PEGylated, fluorescent,and other lipid formulations, while working closely with our Lipid Analysts to ensure Avanti quality.

LNPs are lipid-based drug delivery systems that carry nucleic acid material. These systems primarily rely on four lipid components: a PEG lipid, amino (cationic) lipid, structural lipid, and cholesterol.

Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, is excited to announce the expansion of its Mill Hall high purity excipients facility. This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve lives™. With this latest Mill Hall expansion, Croda continues their ambitious target to become People Positive by 2030 by contributing to the successful development of 25% of WHO-listed pipeline vaccines.

To find out more, please visit: https://www.croda.com/en-gb/news/2021/08/croda-expands-its-high-purity-pharmaceutical-excipients-manufacturing-capability

FDAII Injectable

The coronavirus pandemic has sent seismic shockwaves around the world and forced many global industries into a hiatus. While the crisis has limited the pharmaceutical sector’s activities in terms of R&D and marketing, its supply chains have remained resilient and continued to deliver critical medicines from factory to patient. As the drug development stage rightly focuses on finding vaccines to defeat the virus, those involved further down the product lifecycle are having to plan to ensure that manufacturing and logistics capabilities are ready to deliver any successful vaccines to a potentially global patient population. Using case studies from several senior executives, this report looks at how several key representative companies operating in the pharma supply chain have responded to the huge challenges associated with COVID-19 to ensure that the wheels keep on turning.

Hear from Allyson Maron, one of our Applications Scientists explore the science behind emulsion stabilization. This webinar presents scientific data alongside visual representations. Free product samples are available from our website or by speaking to one of our representatives at Festival of Pharma

Hear from Dr. Will Small and Jasmine Barcock as they showcase the benefits of how high purity ingredients can provide a solution to your formulation challenges, they also delve into our newest excipient innovations and how our approach of providing a specialist solution outweighs ordering a product off the shelf.

Smart Science to Improve Lives. For more than 75 years Croda Denmark has been dedicated to safe and effective adjuvants for use in both human and veterinary vaccines, as well as blood fractioning processes. We offer an experienced passionate team and personal interaction with comprehensive on-site advice and support anywhere in the world.